Declaration of Financial Results for the quarter and year ended march 31, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.9 pts less than Nifty Microcap 250 and 5.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Shukra Pharmaceuticals reported strong full-year performance for FY26 ending March 2026. Standalone revenue grew 74% to Rs 5,671 Lakhs from Rs 3,259 Lakhs, while net profit surged 130% to Rs 2,205 Lakhs from Rs 958 Lakhs. EPS improved from Rs 0.22 to Rs 0.50. However, Q4 FY26 showed weakness with revenue dropping 52% sequentially to Rs 630 Lakhs and a net loss of Rs 173 Lakhs due to high tax expenses (Rs 442 Lakhs) and deferred tax credits reversal. The Board recommended a nominal dividend of Rs 0.01 per share and approved allotment of 17.35 lakh equity shares to promoters (Dakshesh Shah and Parshva Texchem) upon warrant conversion at Rs 25.50 per share. Cash position declined significantly from Rs 1,212 Lakhs to Rs 592 Lakhs due to Rs 1,573 Lakhs capex. The company launched a new MedTech segment from October 2025. Auditors issued an unmodified (clean) opinion.
The strong full-year profit growth of 130% is positive but Q4 weakness and declining cash reserves may concern investors. The large promoter warrant conversion dilutes minority shareholder value in the near term but signals promoter confidence. The small dividend is symbolic.